Daniel O’Day, Gilead Sciences CEO and chairman, joins 'Squawk Box' to discuss the advances in medicine, what to expect at the JPMorgan Healthcare Conference today, the company's Yeztugo HIV medication ...

Beam Therapeutics BEAM is engaged in developing investigational gene therapy candidates that are currently in early-to-mid-stage development for treating certain hematology and genetic diseases. The ...

A recent encounter with a python was like being inside the Anaconda movie. According to Vice Media, "A six-meter [nearly 20-foot] python lunged from a river in Borneo and dragged a local tour guide ...

Add a description, image, and links to the python-glm-pipeline topic page so that developers can more easily learn about it.

Intellia Therapeutics NTLA has made good progress with the advancement of its in vivo candidate, lonvo-z (or, NTLA-2002), which is currently in late-stage development for hereditary angioedema (HAE).

In December, the Book Review Book Club will read and discuss Ian McEwan’s latest novel, about a long-lost poem, the 2014 dinner party where it was read and the future dystopia that embraced it. By MJ ...

Talent doesn’t just follow the money—it responds to new opportunities and improved quality of life offered by new positions. In today’s competitive job market (despite recent softening), companies ...

Neurocrine Biosciences looks meaningfully undervalued, with ongoing growth from Ingrezza, a strong launch for Crenessity, and a promising pipeline. NBIX is looking to grow Ingrezza's market share with ...

Rupali Chakravarti knows all too well what it’s like to fear high costs. The retired math and science teacher rarely shops for clothes. She tries to limit her grocery spending to stay within budget.